10-Q: MaxCyte Q2 Revenue Dips 18% on Lower Milestones

MaxCyte, Inc. reported an 18% decline in total revenue for Q2 2025, primarily due to a significant decrease in non-core program-related revenue, despite an 8% increase in core revenue.

Summary

• Total revenue for the three months ended June 30, 2025, decreased by 18% to $8.5 million, down from $10.4 million in the prior year period.
• Core revenue, which includes instrument sales, processing assemblies (PAs), consumables, research and clinical licenses, and assay services, increased by 8% to $8.2 million for the quarter.
• Non-core Strategic Platform License (SPL) program-related revenue significantly decreased by 89% to $0.3 million for the quarter, compared to $2.9 million in the prior year, due to customer variability in achieving contractual milestones.
• Gross profit for the quarter decreased by 22% to $7.0 million, with gross margin declining to 82% from 86%.
• Net loss for the quarter increased to $12.4 million, or $0.12 per share, compared to a net loss of $9.4 million, or $0.09 per share, in the prior year period.
• For the six months ended June 30, 2025, total revenue decreased by 13% to $18.9 million, while net loss increased to $22.6 million.
• Cash and cash equivalents decreased to $15.2 million as of June 30, 2025, from $27.9 million at December 31, 2024.
• Net cash used in operating activities for the six months ended June 30, 2025, was $24.3 million, an increase from $15.4 million in the prior year period.
• Acquired SeQure Dx, Inc. on January 29, 2025, for a preliminary purchase price of $2.3 million, aiming to strengthen cell and gene therapy services. SeQure contributed $0.3 million in revenue and a $1.9 million net loss for Q2 2025.
• Signed three new SPL agreements in 2025 with TG Therapeutics, Anocca AB, and Adicet Bio.

Sentiment

Score: 4

Explanation: While core revenue showed growth and new SPL agreements were signed, the significant decline in high-margin program-related revenue led to a substantial increase in net loss and cash burn. The company's liquidity position has weakened, and it acknowledges the potential need for future capital raises, indicating financial pressure despite strategic advancements.

Positives

• Core revenue increased by 8% to $8.2 million for the three months ended June 30, 2025, driven by a 22% increase in instrument revenue and a 5% increase in PA revenue.
• Successfully acquired SeQure Dx, Inc. on January 29, 2025, which is expected to strengthen service offerings and leverage commercial teams.
• Entered into three new Strategic Platform License (SPL) agreements in 2025 with TG Therapeutics, Anocca AB, and Adicet Bio, indicating continued expansion of partnerships.
• The ExPERT platform is used by an SPL partner for the first ex-vivo cell therapy approved by the FDA in December 2023, validating the technology.
• Maintained a robust intellectual property portfolio with over 200 granted U.S. and foreign patents and over 100 pending patent applications.

Negatives

• Total revenue decreased by 18% to $8.5 million for the three months ended June 30, 2025, compared to $10.4 million in the prior year.
• Strategic Platform License (SPL) program-related revenue (non-core) significantly decreased by 89% to $0.3 million for the three months ended June 30, 2025, from $2.9 million in the prior year, due to customer variability in milestone achievement.
• Net loss increased to $12.4 million for the three months ended June 30, 2025, from $9.4 million in the prior year period.
• Gross profit decreased by 22% to $7.0 million, and gross margin declined to 82% from 86% for the three months ended June 30, 2025.
• Cash and cash equivalents decreased to $15.2 million as of June 30, 2025, from $27.9 million at December 31, 2024.
• Net cash used in operating activities increased to $24.3 million for the six months ended June 30, 2025, from $15.4 million in the prior year period, indicating increased cash burn.
• Interest income decreased by 28% to $1.9 million for the three months ended June 30, 2025, due to decreases in interest rates and average cash/investment balances.
• SeQure Dx, Inc., acquired in January 2025, contributed a net loss of $1.9 million for the three months ended June 30, 2025.

Risks

• Inability to generate sufficient revenue to achieve profitability, as the company has incurred significant operating losses since inception and expects to continue incurring net losses.
• Variability and uncertainty in the timing of Strategic Platform License (SPL) program-related revenue due to customer achievement of clinical and regulatory milestones.
• Dependence on the program decisions of partners and the availability of capital to support their cell therapy programs.
• Highly competitive market for non-viral delivery, with potential for new Good Manufacturing Practices (GMP) grade platforms from competitors leading to increased price pressure and negative impact on gross margins.
• Concentration of revenue from a few significant customers (one customer represented 25% of Q2 2025 revenue, another 15%).
• Concentration of inventory additions from a single supplier (11% for Q2 2025).
• Risks associated with management transition and the ability to retain and hire senior management and key personnel.
• Exposure to foreign currency fluctuations, although currently not expected to have a material effect.
• Potential need for additional equity or debt financing if unable to adequately fund operations, which could dilute ownership or impose restrictive covenants.
• Uncertainty regarding the successful integration of the acquired SeQure Dx, Inc. business.

Future Outlook

Expects total revenue to increase over time as customer programs advance and markets grow, leading to additional instrument sales, license, and PA sales. Anticipates revenue from PA and instrument sales and instrument licenses to cell therapy customers will continue to grow as programs advance into clinical development and commercialization. Believes the company is well-positioned to attract new customers due to underlying growth in the cell therapy pipeline, capital availability, and a shift towards non-viral approaches. However, revenue may fluctuate due to timing of product sales and licenses, uncertainty of partners' clinical progress, and dependence on partner program decisions. Expects to continue incurring substantial research and development expenses to support customers, develop new uses for technology, and improve/new offerings. Recurring sales and marketing expenses are expected to increase in absolute dollars as teams expand globally and marketing activities increase. General and administrative expenses are also expected to increase due to anticipated headcount growth.

Management Comments

• "We expect program-related revenue to continue to experience variability for some time, although we anticipate that variability may moderate as the volume of SPL partnerships and associated milestones grows and matures."
• "We believe that our continued investment in research and development is essential to our long-term competitive position."
• "We expect to continue to incur substantial research and development expenses as we invest in research and development to support our customers, develop new uses for our existing technology, and develop improved and/or new offerings for our customers and partners."
• "We expect our recurring sales and marketing expenses to increase in absolute dollars in future periods as we expand our commercial sales, marketing and business development teams, expand our product offerings, expand our collaboration efforts, increase our presence globally, and increase marketing activities to drive awareness and adoption of our products."
• "We expect that our general and administrative expenses will continue to increase in absolute dollars in future periods, primarily due to increased headcount to support anticipated growth in the business."
• "Based on our current business plan, we believe that our existing cash, cash equivalents, short-term investments and internally generated cash flows will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the date these consolidated financial statements have been issued."

Industry Context

The company operates in the rapidly expanding cell therapy market, including gene editing and immuno-oncology, as well as drug discovery and biomanufacturing. The filing highlights a growing cell therapy pipeline and a shift by some companies from viral to non-viral delivery approaches, which is favorable for MaxCyte's Flow Electroporation technology. The market for non-viral delivery is competitive, and the introduction of a GMP-grade platform by a competitor could negatively impact business and lead to price pressure. The company's technology is validated by its use in the first FDA-approved ex-vivo cell therapy in December 2023.

Comparison to Industry Standards

• The company's Flow Electroporation technology is used by one of its Strategic Platform License (SPL) partners to engineer the first ex-vivo cell therapy approved by the FDA in December 2023, demonstrating significant validation and commercial relevance.
• The customer base includes a majority of the top 25 pharmaceutical companies based on 2024 global revenue, indicating strong adoption and trust among leading industry players.
• The company states it prices its instruments at a premium due to the broad benefits of its platform and the limited availability of alternative clinically-validated non-viral delivery approaches, suggesting a strong competitive position in its specialized niche.
• The filing notes that the market for non-viral delivery is highly competitive, and the introduction of a Good Manufacturing Practices (GMP) grade platform by a competitor that delivers similar performance across a similar diversity of cell types could negatively impact the business and lead to increased price pressure, setting a benchmark for potential future competitive challenges.

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• Not aware of any pending or threatened legal proceeding against the company that is believed to have a material adverse effect on business, financial condition, or results of operations.

Related Party Transactions

• During the three months ended June 30, 2025, the company sold $18,000 in products and services to a customer whose Board of Directors includes a member who also serves on the company's Board of Directors.
• During the six months ended June 30, 2025, the company sold $20,000 in products and services to a customer whose Board of Directors includes a member who also serves on the company's Board of Directors.
• As of June 30, 2025, the company had $18,000 in accounts receivable from this customer.

Stakeholder Impact

• Shareholders: Increased net loss and cash burn could negatively impact shareholder value. Potential future dilution from capital raises.
• Employees: Increased headcount in R&D and G&A, but reduction in sales and marketing headcount. Stock-based compensation is a significant part of employee compensation.
• Customers: Continued investment in R&D and expansion of product offerings aim to benefit customers. New SPL agreements indicate continued partnership opportunities.
• Suppliers: Concentration risk with one supplier for inventory additions and accounts payable.
• Creditors: No debt obligations currently, but potential future debt financing could introduce new creditor relationships.

Next Steps

• Continue to grow commercial sales of products in both U.S. and international markets.
• Expand sales force and scale manufacturing operations.
• Continue research and development efforts to develop new products and enhance existing ones.
• Focus on successful integration of SeQure Dx, Inc. into the company.
• Continue to build on existing SPL partnerships and develop additional SPL partnerships.
• Monitor the impact of new accounting standards (ASU 2023-09 and ASU 2024-03) on financial disclosures.

Key Dates

Recommendation

The significant decline in total revenue, driven by a sharp drop in high-margin program-related revenue, coupled with an increasing net loss and higher cash burn from operations, indicates deteriorating financial performance. While core revenue showed modest growth and new SPLs were signed, the overall financial trajectory is negative. the company's cash position has notably decreased, and it explicitly mentions the potential need for future capital raises, which could lead to further shareholder dilution. The competitive landscape and dependence on partner milestones add to the uncertainty. Given the current financial results and outlook, a seasoned investor would likely consider selling to mitigate further losses or reallocate capital to more promising opportunities.

Keywords

Cell Engineering, Cell Therapy, Gene Therapy, Biotechnology, Pharmaceutical, Flow Electroporation, ExPERT Platform, Strategic Platform Licenses (SPLs), Assay Services, Drug Discovery, Biomanufacturing, Non-viral Delivery, Immuno-oncology, SEC Filing, 10-Q